Monika Tomaszewska-Kiecana

Statistics

Publications

Citations

H-Index

Active since

2023

Affiliations

Monika Tomaszewska-Kiecana is an author at Incyte (United States) specializing in immunotherapy for solid tumors, programmed cell death protein 1 inhibitors, and optimal dosing regimen design.

ORCID

Publications per year

2023–2024

Publications

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

Nehal J. Lakhani, Rasha Cosman, Udai Banerji et al. · ESMO Open · 2024 · 23 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults

Monika Tomaszewska-Kiecana, Martin Ullmann, Corinne Petit-Frere et al. · Expert Review of Clinical Immunology · 2023 · 10 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

1–2 of 2